263 results
To assess the safety and efficacy of the Orsiro Sirolimus Eluting Coronary Stent System in the treatment of subjects with up to three native de novo or restenotic (standard PTCA only) coronary artery lesions compared to the Xience coronary stent…
The aim of the study is to compare the outcome of two DES with biodegradable polymer coatings separately (Orsiro and Synergy) versus an established third-generation durable polymer DES with proven efficacy and safety (Resolute Integrity) in an all…
To compare the endothelium-dependent and non-endothelium-dependent vasomotion and perfusion restoration in coronary vessels treated with ABSORB BVS or Xience DES in CTO coronary lesions
Primary ObjectivesTo evaluate the effect of MDCO-216 treatment on the change in PAV of a target coronary artery as measured by IVUS imaging following five weekly infusions of MDCO-216 (20 mg/kg) compared with placebo in subjects with a recent ACS.…
The primary objective of this randomized trial is to assess the beneficial effects of early administration of 5 mg Metoprolol intravenously before reperfusion on infarct size in patients with ST elevation myocardial infarction who are planned to…
Primary Objective: To compare the strategies of treatment with 1. ABSORB everolimus eluting bioresorbable vascular scaffolds and 2. Xience everolimus eluting coronary stent system in a non-inferiority all-comers trial.
The primary objective of this study is to assess whether a liberal (6.5 mmol/l) transfusion strategy compared to a restrictive (6.0 mmol/l) transfusion strategy lowers the incidence of major adverse cardiac events (MACE). MACE is defined as a…
To determine in all-comers patients undergoing PCI under standardised treatment (including the BioMatrix family of drug-eluting stents and bivalirudin), whether treatment with 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor…
To evaluate the safety and effectiveness of Orsiro for the treatment of subjects with up to 2 de novo atherosclerotic coronary artery lesions.
Pre-emptive, OCT guided angioplasty of vulnerable, intermediate coronary lesions: a randomized trial
To determine the effect of the stenting of intermediate, vulnerable coronary lesions on the prevention of future ACS, in patients with residual non-obstructive CAD after PCI for myocardial infarction.
The objective of this study is to measure the effect of a smart technology intervention on patients after AMI.
Study goal is to compare the performance of the Absorb bioresorbable scaffold with a metallic drug eltuting stent in the STEMI patient.
1. The primary objective is to assess the effects of four 250 mg PC-mAB (also referred to as "3G10") once monthly intravenous injections on monocyte function ex vivo. The secondary objectives are to:1. assess the functional effects of 3G10…
The primary objective of the FAME 3 Trial is to demonstrate that FFR-guided PCI is noninferior to coronary artery bypass graft surgery in patients with multivessel CAD.
Primary Objective:To compare the fate of the struts in front of the side-branch and intimal bridge formation using optical coherence tomography after treatment with the bioresorbable everolimus eluting vascular scaffold of coronary bifurcation…
Primary Objective: The aim of the study is to show that STEMI patients who are pre-treated with crushed ticagrelor and paracetamol have a higher level of platelet inhibition after primary PCI than patients pre-treated with crushed ticagrelor who are…
The primary objective of this randomized trial is to reduce the HbA1c levels by 10% through exercise training with or without oral anti-diabetic medication in patients with coronary artery disease (PCI or CABG in stable CAD, or post STEMI and post…
The hypothesis of the FAME II trial is that FFR-guided PCI (with DES) plus optimal medical treatment is superior to optimal medical treatment alone. The overall purpose of the FAME II study is to compare the clinical outcomes, safety and cost-…
To assess whether the iFR is non-inferior to FFR when used to guide treamtent of coronary stenoses with PCI
The purpose of the trial is to show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in patients with STE-ACS, with an onset of symptoms of >20 minutes and <12 hours,…